Bumetanide in congestive heart failure.

Article Details

Citation

Copy to clipboard

Kourouklis C, Christensen O, Augoustakis D

Bumetanide in congestive heart failure.

Curr Med Res Opin. 1976;4(6):422-31.

PubMed ID

793779 [ View in PubMed

]

Abstract

Bumetanide, a new diuretic exerting its major effect on the ascending limb of the loop of Henle, was evaluated in 20 patients with congestive heart failure. Dosage ranged from 1 mg to 3 mg daily depending on the patient's condition. The results after 3 and 8 days' treatment showed that bumetanide caused a significant diuresis, an increased excretion of sodium, potassium and chloride, and a comparable fall in the serum levels of these electrolytes. Changes in electrolyte levels were directly related to the dose of the drug. The resultant hypochloraemia was accompanied by a slight metabolic alkalosis. A comparative crossover study between placebo, bumetanide and frusemide using equipotent doses was performed in 10 patients. Both drugs had a similar effect upon water excretion and the serum and urinary electrolytes.

DrugBank Data that Cites this Article

Pharmaco-metabolomics

Drug	Drug Groups	Metabolite	Change	Description
Bumetanide	Approved	Sodium	decreased	Bumetanide decreases the level of Sodium in the blood
Bumetanide	Approved	Chloride	decreased	Bumetanide decreases the level of Chloride in the blood
Bumetanide	Approved	Potassium	decreased	Bumetanide decreases the level of Potassium in the blood